Semaglutide 2.4 mg produced significant and consistent weight loss across racial and ethnic subgroups in the STEP trials, with comparable safety.
Consistent across all groupsSemaglutide 2.4 mg produced significant weight loss regardless of racial or ethnic background in the STEP trials
What the researchers found
Semaglutide 2.4 mg produced significant and consistent weight loss across racial and ethnic subgroups in the STEP trials, with comparable safety profiles.
Why it matters
Obesity disproportionately affects certain racial and ethnic groups. Confirming that semaglutide works across these populations helps ensure equitable treatment access and expectations.
The numbers in context
STEP 1 and 3 data were pooled; STEP 2 analyzed separately. Primary outcome: percent body weight change from baseline. Semaglutide 2.4 mg given once weekly subcutaneously.
How the study worked
Post hoc subgroup analysis of three phase 3 randomized controlled trials (STEP 1, 2, and 3) by race and ethnicity.
Who was studied
Adults with overweight or obesity from the STEP 1, 2, and 3 trials, analyzed by racial and ethnic subgroups
What this study cannot tell us
Post hoc subgroup analysis has less statistical power than a study designed for this comparison. Some subgroups may have been small.
How to read the evidence
Rated strong: post hoc analysis of three large phase 3 randomized controlled trials with explicit subgroup analysis.
When this study was published
Published in 2024. Addresses an important health equity question as GLP-1 drug access expands.
The bigger picture
Obesity disproportionately affects Black, Hispanic, and Native American communities. Confirming that semaglutide works across these populations is essential for equitable treatment access.
Questions still open
- Are there clinically meaningful differences in weight loss magnitude between groups?
- Do cultural and socioeconomic factors affect real-world outcomes differently?
Common questions
Does semaglutide work the same for all races?
Why is racial diversity in drug trials important?
Read the original research
Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.
Obesity (Silver Spring, Md.), 32(7), 1268-1280
Citation
Rubino, Domenica; Angelene, Hanna; Fabricatore, Anthony; Ard, Jamy. (2024). Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.. Obesity (Silver Spring, Md.), 32(7), 1268-1280. https://doi.org/10.1002/oby.24042